Daily Collagen Peptide Supplement Improves Skin Hydration, Elasticity, and Wrinkles in Randomized Controlled Trial

Double-blind, randomized, placebo-controlled trial. 64 participants were randomly assigned to receive 1,000 mg LMWCP or placebo once daily for 12 weeks. Skin hydration, wrinkling (visual and instrumental), and elasticity were assessed at baseline, 6 weeks, and 12 weeks. Safety was monitored throughout.

The collagen supplement market is valued at billions of dollars, but much of the marketing outpaces the evidence. This study provides rigorous clinical trial evidence — the gold standard of double-blind, placebo-controlled design — showing that specific low-molecular-weight collagen peptides do measurably improve skin properties. The characterization of the peptide composition (>15% Gly-X-Y tripeptides) also helps consumers and clinicians identify which collagen products might actually work.

This study adds to a growing body of RCT evidence supporting oral collagen peptide supplementation for skin health. The specific focus on low-molecular-weight peptides with characterized tripeptide content (Gly-X-Y, Gly-Pro-Hyp) is important because it helps establish which peptide forms are bioactive. The results are consistent with the hypothesis that absorbed collagen peptides stimulate fibroblasts to produce new collagen and other extracellular matrix components in the skin.

The sample size (64 participants) is relatively small, and the study duration (12 weeks) is moderate. The participant demographics (age range, sex distribution) are not detailed in the abstract. The study does not include histological or biochemical data to confirm that the measured improvements correspond to actual changes in skin collagen content. The single dose tested (1,000 mg) prevents understanding of dose-response relationships. Long-term maintenance of benefits after stopping supplementation was not assessed.